Analysts Set Quest Diagnostics Incorporated (NYSE:DGX) Price Target at $216.58

Posted by Geri Gentry on May 16th, 2026

Quest Diagnostics Incorporated (NYSE:DGX – Get Free Report) has received a consensus recommendation of “Moderate Buy” from the fourteen brokerages that are currently covering the company, MarketBeat Ratings reports. Seven analysts have rated the stock with a hold recommendation and seven have assigned a buy recommendation to the company. The average 1 year target price among brokers that have updated their coverage on the stock in the last year is $216.5833.

Several analysts have commented on the stock. Evercore set a $225.00 price target on shares of Quest Diagnostics in a research report on Tuesday, April 21st. Mizuho increased their price target on shares of Quest Diagnostics from $210.00 to $235.00 and gave the company an “outperform” rating in a research report on Thursday, February 12th. Wall Street Zen raised shares of Quest Diagnostics from a “hold” rating to a “buy” rating in a research report on Saturday, April 25th. UBS Group increased their price target on shares of Quest Diagnostics from $210.00 to $220.00 and gave the company a “neutral” rating in a research report on Wednesday, April 22nd. Finally, Weiss Ratings raised shares of Quest Diagnostics from a “buy (b)” rating to a “buy (b+)” rating in a research report on Monday, May 4th.

Read Our Latest Stock Analysis on DGX

Insider Activity

In other Quest Diagnostics news, EVP Catherine T. Doherty sold 5,558 shares of the stock in a transaction dated Thursday, March 5th. The shares were sold at an average price of $206.21, for a total transaction of $1,146,115.18. Following the completion of the sale, the executive vice president directly owned 67,122 shares of the company’s stock, valued at approximately $13,841,227.62. This represents a 7.65% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, SVP Patrick Plewman sold 2,855 shares of the stock in a transaction dated Thursday, March 5th. The shares were sold at an average price of $206.21, for a total transaction of $588,729.55. Following the sale, the senior vice president directly owned 15,198 shares of the company’s stock, valued at approximately $3,133,979.58. The trade was a 15.81% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 18,421 shares of company stock valued at $3,790,214. Corporate insiders own 0.88% of the company’s stock.

Hedge Funds Weigh In On Quest Diagnostics

Several hedge funds have recently modified their holdings of the stock. Moneta Group Investment Advisors LLC increased its holdings in shares of Quest Diagnostics by 3.7% during the fourth quarter. Moneta Group Investment Advisors LLC now owns 1,387 shares of the medical research company’s stock valued at $241,000 after acquiring an additional 50 shares in the last quarter. HB Wealth Management LLC increased its holdings in shares of Quest Diagnostics by 0.5% during the fourth quarter. HB Wealth Management LLC now owns 11,292 shares of the medical research company’s stock valued at $1,960,000 after acquiring an additional 58 shares in the last quarter. Independent Advisor Alliance increased its holdings in shares of Quest Diagnostics by 1.4% during the third quarter. Independent Advisor Alliance now owns 4,232 shares of the medical research company’s stock valued at $807,000 after acquiring an additional 59 shares in the last quarter. Ossiam increased its holdings in shares of Quest Diagnostics by 6.1% during the third quarter. Ossiam now owns 1,059 shares of the medical research company’s stock valued at $202,000 after acquiring an additional 61 shares in the last quarter. Finally, Fulton Bank N.A. increased its holdings in shares of Quest Diagnostics by 1.7% during the fourth quarter. Fulton Bank N.A. now owns 4,180 shares of the medical research company’s stock valued at $725,000 after acquiring an additional 68 shares in the last quarter. Institutional investors and hedge funds own 88.06% of the company’s stock.

Quest Diagnostics News Roundup

Here are the key news stories impacting Quest Diagnostics this week:

Positive Sentiment: Zacks Research raised FY2026, FY2027, and Q3 2027 EPS estimates for Quest Diagnostics, signaling improved earnings expectations.
Positive Sentiment: Barron’s highlighted Quest Diagnostics as one of the stocks potentially rebounding after a rough patch, which may support investor interest. Quest Diagnostics, Altria, and 12 More Stocks That Are Coming Back to Life After a Rough Patch
Neutral Sentiment: A new valuation-focused article examined Quest Diagnostics’ investment narrative, but it did not include a direct corporate catalyst. How The Investment Narrative For Quest Diagnostics (DGX) Is Shifting With New Valuation Work
Negative Sentiment: Zacks Research cut estimates for Q2 2026, Q2 2027, Q1 2028, and FY2028 EPS, which could pressure sentiment if investors focus on slower longer-term earnings growth.

Quest Diagnostics Stock Down 0.8%

NYSE:DGX opened at $186.52 on Wednesday. Quest Diagnostics has a 1-year low of $164.65 and a 1-year high of $213.50. The company has a 50-day moving average of $195.72 and a 200 day moving average of $189.92. The firm has a market cap of $20.65 billion, a PE ratio of 20.61, a price-to-earnings-growth ratio of 2.24 and a beta of 0.60. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.18 and a quick ratio of 1.08.

Quest Diagnostics (NYSE:DGX – Get Free Report) last released its quarterly earnings results on Tuesday, April 21st. The medical research company reported $2.50 EPS for the quarter, beating the consensus estimate of $2.37 by $0.13. The business had revenue of $2.90 billion during the quarter, compared to analyst estimates of $2.83 billion. Quest Diagnostics had a net margin of 9.07% and a return on equity of 15.60%. The company’s quarterly revenue was up 9.2% on a year-over-year basis. During the same period in the prior year, the firm posted $1.94 earnings per share. Quest Diagnostics has set its FY 2026 guidance at 10.630-10.830 EPS. As a group, research analysts anticipate that Quest Diagnostics will post 10.72 EPS for the current fiscal year.

Quest Diagnostics announced that its board has approved a stock buyback plan on Tuesday, February 10th that permits the company to buyback $1.00 billion in shares. This buyback authorization permits the medical research company to purchase up to 4.7% of its shares through open market purchases. Shares buyback plans are typically an indication that the company’s board believes its stock is undervalued.

About Quest Diagnostics

(Get Free Report)

Quest Diagnostics (NYSE: DGX) is a leading provider of diagnostic information services that supports clinical decision-making for patients, physicians and healthcare organizations. The company operates a network of clinical laboratories and patient service centers that perform a broad range of laboratory tests and diagnostic assays used in routine care, disease diagnosis, monitoring and screening.

Its services span core clinical laboratory testing, anatomic pathology, molecular and genomic diagnostics, infectious disease testing and toxicology.